281 Use of Monoclonal Antibody Omalizumab in the Treatment of Urticaria Chronic

BACKGROUND: The chronic Urticaria is a real problem of health and a frequent problem in the consultation of the allergist, which the treatment is not to satisfactory. Some Urticaria can be for autoimmunity where the antibody involved is IgE. Omalizumab is an monoclonal antibody against the C3 domain of the epsilon heavy chain of the antibody IgE (domain C3 of the IgE), involved, in allergic problems, which has proved a great utility in asthma off difficult control. METHOD: Five patients of both genders were studied aged between 30 and 45 years, carriers of chronic Urticaria at least of ten years duration. Theirs control was not satisfactory, with the treatment habitual. They were not used glucocorticoids. The clinical evaluation and test of laboratory stated Chronic Urticaria idiopathic. The total IgE was below 100 U. I. The monoclonal antibody Omalizumab applying it for 6 month accorded to habitual schedule. According to dose schedule monoclonal antibody Omalizumab apply the antibody to them, calculating the dose habitual schedule applying for 6 month. According to dose schedule the monoclonal antibody Omalizumab apply to them, it applying for 6 month. RESULTS: All the patient improved their Urticaria between weeks 3 and fort of application of the drug, getting the control of the symptoms between the month 2 and 3 in the 5 patients, without requiring other drugs for their control, and remained asymptomatic for 3 and forth months discontinuity the product up to 6 months, not reactivity the Urticaria, the older case takes now 1 year without activity of his disease. CONCLUSIONS: Omalizumab must be considered to be another therapeutic alternative in patients with idiopathic Urticaria.